Daniel Castellano

Daniel Castellano

UNVERIFIED PROFILE

Are you Daniel Castellano?   Register this Author

Register author
Daniel Castellano

Daniel Castellano

Publications by authors named "Daniel Castellano"

Are you Daniel Castellano?   Register this Author

100Publications

4398Reads

36Profile Views

Update on the management of patients with intermediate and poor-risk testicular germ cell tumors and new biological insights.

Cancer Treat Res Commun 2019 30;19:100117. Epub 2018 Dec 30.

Division of Medical Oncology, 12 de Octubre University Hospital, Avenida de Córdoba s/n 28041 Madrid, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ctarc.2018.100117DOI Listing
September 2019

Cabazitaxel versus Abiraterone or Enzalutamide in Metastatic Prostate Cancer.

N Engl J Med 2019 Sep 30. Epub 2019 Sep 30.

From the Erasmus Medical Center, Rotterdam, the Netherlands (R.W.); the Institute of Cancer Research and the Royal Marsden Hospital, London (J.B.); Englander Institute for Precision Medicine, Weill Cornell Medicine, New York (C.N.S.); Institut Gustave Roussy and University of Paris Sud, Villejuif (K.F.), Jean Godinot Institute and Reims Champagne-Ardenne University, Reims (J.-C.E.), Foch Hospital, Suresnes (C.T.), Hôpital d'Instruction des Armées Bégin, Saint Mandé (C.H.), and Sanofi, Europe Medical Oncology, Paris (C.G.-R.) - all in France; Institut de Recherche Clinique, Université Catholique de Louvain, Louvain, Belgium (B.T.); the Department of Urology, Asklepios Tumorzentrum Hamburg, Asklepios Klinik Altona, Hamburg (C.W.), and Studienpraxis Urologie, Nürtingen (S.F.) - both in Germany; the Medical University of Vienna, Vienna (G.K.); Alexandra Hospital, National and Kapodistrian University of Athens, Athens (A.B.); Vall d'Hebron Institute of Oncology, Vall d'Hebron University Hospital, Barcelona (J.C.); Azienda Ospedaliera Universitaria Integrata, Verona, and Fondazione Policlinico Agostino Gemelli IRCCS, Rome - both in Italy (R.I.); Palacky University Medical School and Teaching Hospital, Olomouc, Czech Republic (B.M.); Landspitali University Hospital, Reykjavik, Iceland (Á.S.); Sanofi, Global Medical Oncology, Cambridge, MA (A.O.); and 12 de Octubre University Hospital, Madrid (D.C.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1911206DOI Listing
September 2019

Vinflunine in the treatment of relapsed metastatic urothelial cancer: A systematic review and meta-analysis of real-world series.

Crit Rev Oncol Hematol 2019 Aug 21;140:80-87. Epub 2019 May 21.

Karolinska University Hospital, Eugeniavägen 3, PO Bäckencancer, Theme Cancer, Solna 17176, Sweden. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.critrevonc.2019.05.006DOI Listing
August 2019

Challenges of treatment selection in the older prostate patient.

J Geriatr Oncol 2019 Jul 20;10(4):666-668. Epub 2019 Jan 20.

Medical Oncology Service, University Hospital 12 de Octubre, Madrid, Spain. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jgo.2019.01.009DOI Listing
July 2019

Best treatment options for advanced renal cell carcinoma (RCC) patients: a Delphi consensus study.

Med Oncol 2019 Feb 19;36(3):29. Epub 2019 Feb 19.

Department of Medical Oncology, Vall d'Hebron Institute of Oncology, Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12032-019-1251-7DOI Listing
February 2019

Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma.

N Engl J Med 2018 Apr 21;378(14):1277-1290. Epub 2018 Mar 21.

From Memorial Sloan Kettering Cancer Center, New York (R.J.M.), and Roswell Park Cancer Institute, Buffalo (S.G.) - both in New York; University of Texas M.D. Anderson Cancer Center, Houston (N.M.T., P. Sharma); Beth Israel Deaconess Medical Center, Dana-Farber/Harvard Cancer Center (D.F.M.), and Dana-Farber Cancer Institute, Brigham and Women's Hospital, and Harvard Medical School (T.K.C.), Boston; Centro Internacional de Estudios Clínicos (O.A.F.) and Fundación Arturo López Pérez (P. Salman), Santiago, Chile; Palacký University and University Hospital Olomouc, Olomouc, Czech Republic (B.M.); Fox Chase Cancer Center, Philadelphia (E.R.P.); Hôpitaux Universitaires de Strasbourg, Strasbourg (P.B.), Bordeaux University Hospital, Hôpital Saint-André, Bordeaux (A.R.), and Institut Gustave Roussy, Villejuif (B.E.) - all in France; Istituto di Ricovero e Cura a Carattere Scientifico San Matteo University Hospital Foundation, Pavia (C.P.), and Ospedale San Donato, Azienda Unità Sanitaria Locale Toscana Sud-Est, Istituto Toscano Tumori, Arezzo (S.B.) - both in Italy; Barts Cancer Institute, Cancer Research UK Experimental Cancer Medicine Centre, Queen Mary University of London, Royal Free NHS Trust (T.P.), and Cancer Research UK (R.H.), London; Aarhus University Hospital, Aarhus, Denmark (F.D.); Davidoff Cancer Center, Rabin Medical Center, Petah Tikva, and Tel Aviv University, Tel Aviv - both in Israel (V.N.); British Columbia Cancer Agency, Vancouver, Canada (C.K.K.); Westmead Hospital and Macquarie University, Sydney (H.G.); Jena University Hospital, Jena, Germany (M.-O.G.); Centro de Pesquisa em Oncologia, Hospital São Lucas, Porto Alegre, Brazil (C.H.B.); Niigata University, Niigata, Japan (Y.T.); Hospital Universitario 12 de Octubre, Madrid (D.C.); Cleveland Clinic Taussig Cancer Institute, Cleveland (B.I.R.); Bristol-Myers Squibb, Princeton, NJ (A.C.C., S.M., M.B.M., M.W.-R., J.D.); and Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore (H.J.H.).

View Article

Download full-text PDF

Source
http://www.nejm.org/doi/10.1056/NEJMoa1712126
Publisher Site
http://dx.doi.org/10.1056/NEJMoa1712126DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5972549PMC
April 2018

Cabozantinib, a New Standard of Care for Patients With Advanced Renal Cell Carcinoma and Bone Metastases? Subgroup Analysis of the METEOR Trial.

J Clin Oncol 2018 03 8;36(8):765-772. Epub 2018 Jan 8.

Bernard Escudier, Institut Gustave Roussy, Villejuif; Stephane Oudard, Hôpital Européen Georges Pompidou, Paris; Frederic Rolland, Centre René Gauducheau Centre de Lutte Contre Le Cancer Nantes, Saint-Herblain, France; Thomas Powles, Barts Cancer Institute, Queen Mary University of London, London, United Kingdom; Robert J. Motzer, Memorial Sloan Kettering Cancer Center, New York, NY; Thomas Olencki, Ohio State University, Columbus, OH; Osvaldo Arén Frontera, Centro Internacional de Estudios Clinicos, Santiago, Chile; Piotr Tomczak, Szpital Kliniczny Przemienienia Panskiego Uniwersytetu Medycznego, Poznań, Poland; Daniel Castellano, Hospital Universitario 12 de Octubre, Madrid, Spain; Leonard J Appleman, University of Pittsburgh Medical Center, Pittsburgh, PA; Harry Drabkin, Medical University of South Carolina, Charleston, SC; Daniel Vaena, University of Iowa Hospitals and Clinics, Iowa City, IA; Steven Milwee, Jillian Youkstetter, and Julie C. Lougheed, Exelixis, Inc., San Francisco, CA; Sergio Bracarda, Ospedale San Donato, Istituto Toscano Tumori (ITT), Arezzo, Italy; and Toni K. Choueiri, Dana-Farber Cancer Institute, Boston, MA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2017.74.7352DOI Listing
March 2018

Cabazitaxel Versus Docetaxel As First-Line Therapy for Patients With Metastatic Castration-Resistant Prostate Cancer: A Randomized Phase III Trial-FIRSTANA.

J Clin Oncol 2017 Oct 28;35(28):3189-3197. Epub 2017 Jul 28.

Stéphane Oudard, Georges Pompidou European Hospital, Rene Descartes University; Mustapha Chadjaa; Sanofi, Paris; Karim Fizazi, Institut Gustave Roussy, University of Paris Sud, Villejuif; Antoine Thiery-Vuillemin, Centre Hospitalier Universitaire Minjoz Besançon, Besançon, France; Lisa Sengeløv, Herlev Hospital, Herlev; Gedske Daugaard, Copenhagen University Hospital, Rigshospitalet, Copenhagen; Steinbjørn Hansen, Odense University Hospital, Odense, Denmark; Fred Saad, Centre Hospitalier de l'Université de Montréal, Montréal, Quebec, Canada; Marie Hjälm-Eriksson, Karolinska University Hospital, Stockholm, Sweden; Jacek Jassem, Medical University of Gdansk, Gdansk, Poland; Orazio Caffo, Santa Chiara Hospital, Trento, Italy; Daniel Castellano, University Hospital 12 de Octubre, Madrid, Spain; Paul N. Mainwaring, Icon Cancer Care, Brisbane, Queensland, Australia; John Bernard, Sanofi, Cambridge, MA; Liji Shen, Sanofi, Bridgewater, NJ; and Oliver Sartor, Tulane Cancer Center, New Orleans, LA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2016.72.1068DOI Listing
October 2017

Evaluation of KDR rs34231037 as a predictor of sunitinib efficacy in patients with metastatic renal cell carcinoma.

Pharmacogenet Genomics 2017 06;27(6):227-231

aHereditary Endocrine Cancer Group, Spanish National Cancer Research Centre (CNIO) bOncology Department, Hospital Universitario 12 de Octubre cSpanish Oncology Genitourinary Group (SOGUG) dISCIII Center for Biomedical Research on Rare Diseases (CIBERER), Madrid, Spain eDepartment of Clinical Pharmacy and Toxicology fDepartment of Medical Oncology gDepartment of Medical Statistics and Bioinformatics, Leiden University Medical Center, Leiden hDepartment of Medical Oncology, VU University Medical Center, Amsterdam iDepartment of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands jDepartment of Solid Tumour Oncology, Cleveland Clinic Foundation (CCF) Taussig Cancer Institute, Cleveland, Ohio, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/FPC.0000000000000280DOI Listing
June 2017

The role of mTOR inhibition as second-line therapy in metastatic renal carcinoma: clinical evidence and current challenges.

Expert Rev Anticancer Ther 2017 03 20;17(3):217-226. Epub 2017 Jan 20.

g Servicio de Oncología Médica , Hospital 12 de Octubre , Madrid , Spain.

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/14737140.2017.1
Publisher Site
http://dx.doi.org/10.1080/14737140.2017.1273774DOI Listing
March 2017

Prognostic Significance of Venous Thromboembolic Events in Disseminated Germ Cell Cancer Patients.

J Natl Cancer Inst 2017 01 25;109(4). Epub 2017 Jan 25.

Affiliations of authors: Hospital Universitario Morales Meseguer-IMIB, Murcia, Spain (EGB, MIL, ACB, FAdlP); Universidad Católica San Antonio de Murcia (UCAM), Murcia, Spain (EGB); Hospital Universitario 12 de Octubre, Madrid, Spain (DC, RM); Instituto Nacional de Cancerología, Mexico DF, Mexico (NS, JLA); Hospital San Joan de Reus, IISSPV, URV, Spain (JG); Instituto de Investigación Sanitaria La Fe, Valencia, Spain (DH); Hospital Universitario La Fe, Valencia, Spain (JA); Investigación Clínica y Traslacional en Cáncer/Instituto de Investigaciones Biomédicas de Málaga (IBIMA)/Hospitales Universitarios Regional y Virgen de la Victoria de Málaga, Málaga, Spain (ASM); Servicio de Oncología Médica, Hospital Clinic, IDIBAPS, Barcelona, Spain (BM); Hospital Clinico Lozano Blesa, Zaragoza, Spain (AS); Hospital Universitario Vall d'Hebron, Barcelona, Spain (CV); Complejo Hospitalario Universitario de Albacete, Albacete, Spain (AF); Institut Català d'Oncologia-Hospital Germans Trias i Pujol, Badalona, Spain (MM); Hospital Universitario Virgen del Rocío, Sevilla, Spain (ID); Hospital Central de Asturias, Oviedo, Spain (SF); Hospital Clínico San Carlos, Madrid, Spain (JS); Hospital Virgen de la Arrixaca, Murcia, Spain (SRo); Hospital de la Santa Creu i Sant Pau, Barcelona, Spain (PM); Hospital Santa Lucía, Cartagena, Spain (PC); Hospital de Oncología, Centro Médico Nacional SXXI, México DF, México (SRi); Institut Catala d'Oncologia, Barcelona, Spain (XGdM, JRGL).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/jnci/djw265DOI Listing
January 2017

Type 2 diabetes is associated with decreased PGC1α expression in epicardial adipose tissue of patients with coronary artery disease.

J Transl Med 2016 08 19;14(1):243. Epub 2016 Aug 19.

Unidad de Gestión Clínica Área del Corazón, Instituto de Investigación Biomédica de Málaga (IBIMA), Hospital Universitario de Málaga (Virgen de la Victoria), Universidad de Málaga, Red de Investigación Cardiovascular (RIC), Málaga, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12967-016-0999-1DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4992233PMC
August 2016

Randomized Open-Label Phase II Trial of Apitolisib (GDC-0980), a Novel Inhibitor of the PI3K/Mammalian Target of Rapamycin Pathway, Versus Everolimus in Patients With Metastatic Renal Cell Carcinoma.

J Clin Oncol 2016 05 7;34(14):1660-8. Epub 2016 Mar 7.

Thomas Powles, Queen Mary University of London, London; Christy Ralph, University of Leeds, Leeds; Janet E. Brown, University of Sheffield, Sheffield; Robert E. Hawkins, University of Manchester, Manchester, United Kingdom; Mark R. Lackner, Wei Lin, Bridget O'Keeffe, Yulei Wang, Shan Lu, Jill M. Spoerke, Ling Yuh Huw, Michelle Byrtek, Rui Zhu, and Joseph A. Ware, Genentech, South San Francisco, CA; Robert J. Motzer, Memorial Sloan Kettering Cancer Center, New York, NY; Brian I. Rini, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH; Bernard Escudier, Institut Gustave Roussy, Villejuif; Alain Ravaud, Hospital Saint Andre, Bordeaux; Stéphane Oudard, University Paris Descartes, Paris, France; Daniel Castellano, University Hospital 12 de Octubre, Madrid, Spain; and Michael D. Staehler, University Hospital Munich-Grosshadern, Marchioninistrasse, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2015.64.8808DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5569691PMC
May 2016

Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma.

N Engl J Med 2015 Nov 25;373(19):1803-13. Epub 2015 Sep 25.

From Memorial Sloan Kettering Cancer Center, New York (R.J.M.), and Roswell Park Cancer Institute, Buffalo (S.G.) - both in New York; Institut Gustave Roussy, Villejuif (B.E.), and Bordeaux University Hospital, Hôpital Saint André, Bordeaux (A.R.) - both in France; Beth Israel Deaconess Medical Center (D.F.M.) and Dana-Farber Cancer Institute, Brigham and Women's Hospital, and Harvard Medical School (T.K.C.) - all in Boston; Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore (H.J.H.); Stanford Cancer Institute, Stanford, CA (S.S.); University of Washington and Fred Hutchinson Cancer Research Center, Seattle (S.S.T.); Vanderbilt University Medical Center, Nashville (J.A.S.); Fondazione Istituto Nazionale Tumori, Milan (G.P.); Fox Chase Cancer Center, Philadelphia (E.R.P.); Hospital Universitario 12 De Octubre, Madrid (D.C.); Westmead Hospital and Macquarie University, Sydney (H.G.); Aarhus University Hospital, Aarhus, Denmark (F.D.); Helsinki University Central Hospital and University of Helsinki, Helsinki (P.B.); South West Wales Cancer Institute and Swansea University College of Medicine, Swansea (J.W.), and Royal Marsden Hospital, London (J.L.) - both in the United Kingdom; University Hospital Essen of University of Duisburg-Essen, Germany (T.C.G.); Chiba Cancer Center, Chiba (T.U.), and Niigata University, Niigata (Y.T.) - both in Japan; Hospital Sao Jose, Beneficencia Portuguesa de São Paulo, São Paulo (F.A.S.); British Columbia Cancer Agency, Vancouver, BC, Canada (C.K.); Bristol-Myers Squibb, Lawrenceville (J.S.S., I.M.W.) and Hopewell (L.-A.X.) - both in New Jersey; and M.D. Anderson Cancer Center, University of Texas, Houston (P.S.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1510665DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5719487PMC
November 2015

CYP3A5 and ABCB1 polymorphisms as predictors for sunitinib outcome in metastatic renal cell carcinoma.

Eur Urol 2015 Oct 27;68(4):621-9. Epub 2015 Apr 27.

Department of Clinical Pharmacy and Toxicology, Leiden University Medical Centre, Leiden, The Netherlands; Dutch working group focusing on sunitinib-induced toxicity (SUTOX consortium), The Netherlands. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.eururo.2015.04.018DOI Listing
October 2015

Analysis of the Polycomb-related lncRNAs HOTAIR and ANRIL in bladder cancer.

Clin Epigenetics 2015 8;7:109. Epub 2015 Oct 8.

Molecular Oncology Unit, CIEMAT (ed70A), Av Complutense 40, 28040 Madrid, Spain ; Biomedical Research Institute I+12, University Hospital "12 de Octubre", Av Córdoba s/n., 28041 Madrid, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13148-015-0141-xDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4599691PMC
October 2015

Expert consensus for the management of advanced or metastatic pancreatic neuroendocrine and carcinoid tumors.

Cancer Chemother Pharmacol 2015 Jun 6;75(6):1099-114. Epub 2014 Dec 6.

Departamento de Oncología Médica, Hospital Universitario 12 de Octubre, Avda. de Córdoba s/n, 28041, Madrid, Spain,

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00280-014-2642-2DOI Listing
June 2015

Cabazitaxel for metastatic castration-resistant prostate cancer: safety data from the Spanish expanded access program.

Expert Opin Drug Saf 2014 Sep 7;13(9):1165-73. Epub 2014 Jul 7.

University Hospital 12 de Octubre, Medical Oncology Department, Urooncology Unit (I+12 Research Institute) , Avda. de Cordoba, s/n, 28041 Madrid , Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1517/14740338.2014.939583DOI Listing
September 2014

Recommendations from the Spanish Oncology Genitourinary Group for the treatment of patients with renal cell carcinoma.

Cancer Chemother Pharmacol 2014 Jun 16;73(6):1095-107. Epub 2014 Feb 16.

Genitourinary and Sarcoma Unit, Department of Medical Oncology, Institut Català d'Oncologia L'Hospitalet, Gran Via de L'Hospitalet, 199-203, 08908, L'Hospitalet, Barcelona, Spain,

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00280-014-2413-0DOI Listing
June 2014

Phase II results of Dovitinib (TKI258) in patients with metastatic renal cell cancer.

Clin Cancer Res 2014 Jun 1;20(11):3012-22. Epub 2014 Apr 1.

Authors' Affiliations: Institut de Cancérologie Gustave Roussy, Villejuif; Hôpital Saint-André, Bordeaux University Hospital, Bordeaux, France; Medizinische Hochschule Hannover, Hannover; Technische Universität München, Munich, Germany; Taichung Veterans General Hospital, National Yang-Ming University School of Medicine; National Taiwan University Hospital, Taipei, Taiwan; 12 de Octubre University Hospital, Madrid, Spain; University of California, San Francisco, San Francisco, California; Novartis Pharmaceuticals Corporation, East Hanover, New Jersey; and Novartis Pharma AG, Basel, Switzerland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-13-3006DOI Listing
June 2014

Randomized, placebo-controlled, phase III trial of sunitinib plus prednisone versus prednisone alone in progressive, metastatic, castration-resistant prostate cancer.

J Clin Oncol 2014 Jan 9;32(2):76-82. Epub 2013 Dec 9.

M. Dror Michaelson, Massachusetts General Hospital Cancer Center, Boston, MA; Stephane Oudard, George Pompidou European Hospital, Rene Descartes University, Paris; Nadine Houede, Institut Bergonie, Bordeaux; Tristan Maurina, CHU de Besançon, Hôpital Jean Minjoz, Besançon, France; Yen-Chuan Ou, Taichung Veterans General Hospital, Taichung, Taiwan; Lisa Sengeløv, Herlev Hospital, Herlev; Gedske Daugaard, Rigshospitalet, Copenhagen, Denmark; Fred Saad, University of Montreal, Montreal, Canada; Peter Ostler, Mount Vernon Hospital, Northwood, Middlesex; Robert Jones, Beatson West of Scotland Cancer Centre, Glasgow; Amit Bahl, Bristol Haematology and Oncology Centre, Bristol, UK; Arnulf Stenzl, Eberhard-Karls-University Medical School, Tübingen; Juergen Gschwend, Technical University of Munich, Munich, Germany; Fredrik Laestadius and Anders Ullèn, Karolinska University Hospital, Stockholm, Sweden; Daniel Castellano, I_12 Research Institute, University Hospital 12 de Octubre, Madrid, Spain; Edna Chow Maneval, Shaw-Ling Wang, and Isan Chen, Pfizer Oncology, La Jolla, CA; and Maria Jose Lechuga and Jolanda Paolini, Pfizer Oncology, Milan, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2012.48.5268DOI Listing
January 2014

The targeted therapy revolution in neuroendocrine tumors: in search of biomarkers for patient selection and response evaluation.

Cancer Metastasis Rev 2013 Dec;32(3-4):465-77

Oncology Institute of Southern Switzerland, Bellinzona, Switzerland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10555-013-9421-0DOI Listing
December 2013

The role of pharmacogenomics in metastatic renal cell carcinoma.

Cancer Metastasis Rev 2012 Sep;31 Suppl 1:S29-32

Hospital Universitario 12 de Octubre, Madrid, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10555-012-9356-xDOI Listing
September 2012

The optimize project: beyond first-line therapy in metastatic renal cell carcinoma.

Cancer Metastasis Rev 2012 Sep;31 Suppl 1:S1-2

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10555-012-9393-5DOI Listing
September 2012

Recommendations for the optimal management of early and advanced urothelial carcinoma.

Cancer Treat Rev 2012 Aug 23;38(5):431-41. Epub 2011 Nov 23.

Medical Oncology Department, Hospital Universitario 12 de Octubre, Avda. De Córdoba, S/N. 28041 Madrid, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ctrv.2011.10.004DOI Listing
August 2012

Gastroenteropancreatic neuroendocrine tumor cancer stem cells: do they exist?

Cancer Metastasis Rev 2012 Jun;31(1-2):47-53

Servicio de Oncología Médica, Hospital Universitario Ramón y Cajal de Madrid, Madrid, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10555-011-9328-6DOI Listing
June 2012

[Hormonal treatment in biochemical recurrence after radical prostatectomy].

Arch Esp Urol 2012 Jan-Feb;65(1):111-21

Servicios de Urología, Oncología Radioterápica y Oncología Médica, España.

View Article

Download full-text PDF

Source
June 2012

Castration-resistant metastatic prostate cancer: current status and treatment possibilities.

Clin Transl Oncol 2012 Mar;14(3):169-76

Servicio de Oncología, Instituto de Oncología de la Vall d'Hebron, Barcelona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12094-012-0780-8DOI Listing
March 2012

Experience in the use of sunitinib given as a single agent in metastatic chemoresistant and castration-resistant prostate cancer patients.

Expert Opin Pharmacother 2011 Nov 15;12(16):2433-9. Epub 2011 Jun 15.

Medical Oncology Department, 12 de Octubre University Hospital, Av. Córdoba Km 5,4, PO Box 28041, Madrid, Spain.

View Article

Download full-text PDF

Source
http://www.tandfonline.com/doi/full/10.1517/14656566.2011.59
Publisher Site
http://dx.doi.org/10.1517/14656566.2011.590132DOI Listing
November 2011

Advances in pancreatic neuroendocrine tumor treatment.

N Engl J Med 2011 05;364(19):1872-3; author reply 1873-4

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMc1102746DOI Listing
May 2011

Gastroenteropancreatic neuroendocrine tumors. Where are we now?

Cancer Metastasis Rev 2011 Mar;30 Suppl 1

Departamento de Oncología Médica, Hospital Universitario 12 de Octubre, Avda. de Córdoba, s/n, 28041, Madrid, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10555-011-9296-xDOI Listing
March 2011